MADRIGAL PHARMACEUTICALS, INC. Accrued Liabilities, Current
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Accrued Liabilities, Current of $338.66 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Accrued Liabilities, Current $338.66M.
- 2026-03-31: Accrued Liabilities, Current $275.76M.
- 2025-12-31: Accrued Liabilities, Current $260.39M.
- 2025-09-30: Accrued Liabilities, Current $345.38M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $338.66M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $275.76M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $260.39M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $345.38M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $157.48M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $124.17M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $124.69M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $131.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $115.61M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $92.27M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $89.98M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $82.61M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $81.76M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $85.57M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $91.46M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $79.60M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $71.84M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $53.44M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $55.05M 10-K/A · filed 2023-03-03 | |
| 2021-09-30 | $58.50M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $55.24M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $44.08M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $45.22M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $42.77M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $39.95M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $24.27M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $23.64M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $14.38M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $11.56M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $5.78M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $5.96M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $5.61M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $4.85M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $4.87M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $8.13M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $7.12M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $5.15M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $3.13M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $4.04M 10-K · filed 2018-03-13 | $4.04M 10-K · filed 2017-03-31 |
| 2016-09-30 | $2.76M 10-Q/A · filed 2017-03-31 | |
| 2015-12-31 | $70.20K 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |